X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (15) 15
female (13) 13
oncology (10) 10
middle aged (9) 9
adult (8) 8
index medicus (8) 8
male (8) 8
aged (6) 6
research (5) 5
aged, 80 and over (4) 4
breast cancer (4) 4
chemotherapy (4) 4
disease-free survival (4) 4
prognosis (4) 4
risk factors (4) 4
adolescent (3) 3
breast neoplasms - genetics (3) 3
follow-up studies (3) 3
hematology (3) 3
medicine, general & internal (3) 3
melanoma (3) 3
mutation (3) 3
neoplasm staging (3) 3
skin neoplasms - pathology (3) 3
abridged index medicus (2) 2
administration, oral (2) 2
analysis (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
breast neoplasms - drug therapy (2) 2
breast neoplasms - mortality (2) 2
cancer (2) 2
cancer therapies (2) 2
care and treatment (2) 2
dermatology (2) 2
genetic aspects (2) 2
genetic predisposition to disease (2) 2
hematology, oncology and palliative medicine (2) 2
heterozygote (2) 2
italy (2) 2
medical research (2) 2
medicine & public health (2) 2
medicine, experimental (2) 2
melanoma - genetics (2) 2
melanoma - pathology (2) 2
metaanalysis (2) 2
model (2) 2
non-hodgkin's lymphoma (2) 2
non-hodgkins-lymphoma (2) 2
postmenopausal women (2) 2
predictive value of tests (2) 2
prevention (2) 2
risk (2) 2
skin neoplasms - genetics (2) 2
stem-cell transplantation (2) 2
survival analysis (2) 2
survival rate (2) 2
07.05.fb; 13.20.eb; 29.40.vj; 29.27.eg (1) 1
1506 (1) 1
1717 (1) 1
1st complete remission (1) 1
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (1) 1
acute lymphoblastic leukaemia (1) 1
acute lymphocytic-leukemia (1) 1
adherence (1) 1
adverse events (1) 1
age (1) 1
algorithms (1) 1
alleles (1) 1
antigen-positive patients (1) 1
antigens, neoplasm - blood (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic agents, hormonal - adverse effects (1) 1
antineoplastic agents, hormonal - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
arimidex (1) 1
aromatase (1) 1
aromatase - genetics (1) 1
aromatase inhibitors (1) 1
article (1) 1
ascertainment sampling problem (1) 1
asthma (1) 1
ataxia-telangiectasia (1) 1
automation (1) 1
b-lineage all (1) 1
biomarkers - blood (1) 1
biomarkers, tumor - blood (1) 1
blood coagulation (1) 1
bone-marrow-transplantation (1) 1
brca2 (1) 1
brca2 protein (1) 1
brca2-interacting protein (1) 1
breast neoplasms (1) 1
breast neoplasms - blood (1) 1
breast neoplasms - congenital (1) 1
breast neoplasms - diagnosis (1) 1
breast neoplasms - epidemiology (1) 1
breast neoplasms - pathology (1) 1
breast-cancer (1) 1
breast-cancer risk (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 848 - 858
Journal Article
Journal Article
CANCER, ISSN 0008-543X, 11/1989, Volume 64, Issue 10, pp. 2014 - 2018
Journal Article
Annals of Oncology, ISSN 0923-7534, 05/2019, Volume 30, Issue 5, pp. 766 - 773
Abstract Background Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on... 
paclitaxel | first line | pertuzumab | dual HER2 blockade | HER2-positive | metastatic breast cancer | WEEKLY PACLITAXEL | ONCOLOGY | NAB-PACLITAXEL | PROGRESSION-FREE SURVIVAL | DOCETAXEL
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2014, Volume 371, Issue 6, pp. 497 - 506
Journal Article
Journal Article